AstraZeneca CEO Pascal Soriot (Raphael Lafargue/Abaca/Sipa USA)

A com­bo of As­traZeneca's Imfinzi and chemo wins where oth­ers have failed in piv­otal bil­iary tract test

Look­ing to run with the big dogs in the PD-(L)1 class, As­traZeneca’s Imfinzi has a tall hill to climb to com­pete in an in­creas­ing­ly bustling mar­ket. An ag­gres­sive com­bo strat­e­gy for the drug has paid off so far, and now As­traZeneca is adding an­oth­er notch to its belt.

A com­bo of Imfinzi (dur­val­um­ab) and chemother­a­py sig­nif­i­cant­ly ex­tend­ed the lives of first-line pa­tients with ad­vanced bil­iary tract can­cer over chemo alone, ac­cord­ing to topline re­sults from the Phase III TOPAZ-1 study re­vealed Mon­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA